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Design of dry powder formulations of pH responsive 
peptide/plasmid DNA complexes for pulmonary delivery 
Introduction Materials and Methods 
Successful pulmonary nucleic acid therapy necessitates efficient delivery 
of the therapeutic gene to the lung. Delivery by inhalation is desirable for 
the treatment of lung diseases as the therapeutic nucleic acids can be 
applied locally to the affected site and minimize systemic adverse effects 
[1]. Previously, our group has demonstrated the use of histidine-rich 
amphipathic peptide, LAH4-L1, to deliver nucleic acids effectively to 
human lung epithelial cells, to achieve high transfection efficiency [2]. 
The cationic peptide can bind and condense nucleic acids through 
electrostatic interaction to form nano-sized complexes for efficient 
cellular uptake and promote endosomal escape.  
Peptide: LAH4-L1 (KKALLAHALHLLALLALHLAHALKKA) 
were synthesized (>70% purity) by ChinaPeptide (Shanghai, China). 
Plasmid DNA: gWIZ™luc (expressing luciferase) was purchased from 
Aldevron (Fargo, ND,USA). Mannitol: Pearlitol 160C was purchased 
from Roquette (Lestrem, France). 
 
Preparation of Spray Dried (SD) and Spray Freeze Dried (SFD) 
Powders 
Mannitol: LAH4-L1: DNA (1000: 10: 1, by weight) was dissolved in 
water with a final concentration of mannitol at 10 mg/ml. The solutions 
were subjected to spray drying (Büchi B-191 Mini Spray Dryer) or spray 
freeze drying (ultrasonic atomizer nozzle). 
DNA Integrity DNA was extracted from the powders and the re-
suspended samples were evaluated by gel retardation assay. 
Morphology The morphology of the SD and SFD powders were 
observed by scanning electron microscopy (Hitachi S4800 FEG SEM). 
Transfection To evaluate the biological activity of the dry powders, in 
vitro transfection experiments were performed on A549 cells. The 
powders were resuspended in culture media before adding to the A549 
cells. The transfection efficiency was assessed by luciferase assay at 48 h 
post-transfection. 
Objectives 
1.To prepare and characterize the spray dried and spray freeze dried 
powder formulations of LAH4-L1/DNA for inhalation 
2.To evaluate and compare the biological activities of the spray dried and 
spray freeze dried powders 
Results and Discussions 
Shear forces and extreme temperatures typically encountered during the 
drying processes may cause DNA degradation. The gel retardation assay 
(Fig. 1) showed that the structure of plasmid DNA could be successfully   
preserved after SD and SFD. The extracted DNA adopted a more relaxed 
structure compared to the original supercoiled structure. The significant 
of this is uncertain because the level of supercoiling of plasmid DNA is 
not known to affect the transfection efficiency significantly [3]. 
 
The SD and SFD powders show a spherical morphology (Fig. 2), with 
SD powder surface slightly corrugated. The SD powder particle diameter 
was around 1-2 μm. The SFD powders were highly porous with particle 
diameters about 20-40 μm. 
 
The transfection efficiency of SD powder formulation was significantly 
increased compared to that of the freshly prepared LAH4-L1/DNA 
complexes (Fig. 3A). The presence of mannitol in the formulation may 
enhance the cellular uptake of the DNA complexes. Although the peptide 
based formulations were less efficient than Lipofectamine™ 2000, they 
were significantly less toxic as shown in the protein assay (Fig. 3B). 
 
Fig.1 Gel electrophoresis of 
DNA extracted from the 
dry powder formulations 
on 1% agarose gel. DNA 
was stained with GelRed™ 
stain. 
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Fig.2 Scanning electron micrographs of the dry powder formulation: 
(A) SD powders at x2,000 magnification; 
(B) SD powders at x40,000 magnification; 
(C) SFD powders at x2,000 magnification; 
(D) SFD powders at x3,500 magnification. 
Fig. 3 Transfection of LAH4-L1/DNA formulations on A549 cells. 
(A) Transfection efficiency expressed as relative light units (RLU)/mg protein; 
(B) Cellular protein level of cells after transfection.  
Bar indicates mean ± SD (n = 6-8). *** p <0.001. 
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